Background: International cancer surveillance initiatives consistently show that population-level cancer outcomes depend not only on scientific advances, but also on health system capacity to ensure timely and equitable access to innovation. In low- and middle-income countries (LMICs), structural and informational barriers often prevent patients from benefiting from advances generated through clinical research, contributing to persistent survival inequalities. In Brazil, although the number of oncology and onco-hematology clinical trials has increased substantially, participation remains highly centralized. Information on ongoing trials is fragmented, limiting systematic identification and referral of eligible patients—particularly those treated within the public healthcare system—and hindering both trial accrual and equitable access to investigational therapies.

Objectives: To describe the development and early implementation of Let Me Trial, an academically founded digital platform designed as a national clinical trial navigation and referral tool for patients and physicians in Brazil, and to evaluate its initial contribution to improving access to clinical research, system efficiency, and equity in cancer care within an LMIC context.

Methods: Let Me Trial is a science-based digital health platform developed by an academic spin-off healthtech incubated at Tecnopuc/Biohub–PUCRS (Brazil), operating under a hybrid academic–commercial model with governance mechanisms to preserve public-interest objectives. The platform is free of charge and functions as a system-level intervention by systematically identifying, mapping, and curating all active oncology and onco-hematology clinical trials conducted nationwide. Public trial registries (ClinicalTrials.gov and WHO ICTRP) are integrated via API and complemented by structured academic curation. The platform supports clinicians in identifying relevant studies, reviewing eligibility criteria, and referring patients following informed consent, while the Let Me Trial team provides patients with guided navigation through research pathways. All processes comply with Brazilian data protection legislation (LGPD) and international ethical research standards. Implementation outcomes were assessed descriptively from April 2025 onwards using indicators of reach, referral, and enrollment.

Results: Since April 2025, the intervention has achieved nationwide coverage of active oncology and onco-hematology clinical trials in Brazil, with daily updates of newly registered studies. More than 250 clinicians and patients from multiple regions engaged with the platform through structured educational and orientation activities, receiving information on cancer research processes, clinical trial participation, and eligibility pathways. Thirdy-two patients were actively navigated for trial screening and inclusion, including patients treated within the public healthcare system.

Conclusions / Implications: This early experience suggests that academically driven digital platforms can reduce structural barriers to cancer clinical trial access in LMICs by improving information transparency, patient education, and referral pathways. By supporting both clinicians and patients, such approaches may expand equitable access to investigational therapies and better align clinical research with population health needs. Embedding these platforms within academic and cancer control systems may strengthen the translation of clinical research into real-world public health impact.
No promotional activities were conducted. Findings reflect early-stage implementation outcomes, with no claims of clinical efficacy.